AstraZeneca vaccine co-inventors' float on US market is a blow to the UK - but it's not all bad news Thursday 8th April 2021 15:15 BST Instead, in what will be seen as a blow to the government's ambitions to make the UK stock market a hub for fast-growing technology and life sciences companies, Vaccitech is to float in the United States. The company was valued at around $425m (£308m) at its most recent funding round, only last month, in which it raised $168m (£122m) from investors including the fund management giant M&G. However, the Wall Street Journal reported last month that the company would be seeking a valuation of $700m (£508m) on flotation, while there has even been speculation that it could be worth as much as $1bn (£730m) by the end of the year.